智翔金泰(688443.SH)：GR1803注射液系统性红斑狼疮适应症获批临床试验

Group 1 - The core point of the article is that Zhixiang Jintai (688443.SH) has received approval from the National Medical Products Administration for the clinical trial of its product GR1803 injection for systemic lupus erythematosus (SLE) [1] - As of the announcement date, GR1803 injection is in the Phase II clinical trial stage for relapsed/refractory multiple myeloma [1] - There are currently two imported BCMA×CD3 targeted antibody drugs conditionally approved for marketing in China, but no products targeting the same SLE indication have been launched [1]